TRIGEMX
LIVE

Serial Number

50097858

Owner

Kallyope, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Sep 9, 2026

Add to watchlist:

No watchlists yet
View on USPTO

TRIGEMX Trademark

Serial Number: 50097858

TRIGEMX is a trademark filed by Kallyope, Inc. on September 9, 2026. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Kallyope, Inc. (2 trademarks)

New York, NY 10016

Entity Type: 03

Trademark Details

Filing Date

September 9, 2026

Registration Date

Not Registered

Goods & Services

Active chemical ingredients for use in the manufacture of pharmaceuticals for the treatment of gastrointestinal diseases, metabolic diseases, microbiome related conditions, and neurological diseases and disorders, and any disease or disorder associated with intestinal permeability; biochemicals for in vitro and in vivo scientific or research use; Active chemical ingredients for scientific or research use in the manufacture of pharmaceuticals for the treatment of gastrointestinal diseases, metabolic diseases, microbiome related conditions, and neurological diseases and disorders, and any disease or disorder associated with intestinal permeability

pharmaceutical preparations and substances for the treatment of gastrointestinal diseases, metabolic diseases, microbiome-related conditions, neurological diseases and disorders, and diseases and disorders associated with intestinal permeability; pharmaceutical preparations and substances for treatment of diseases related to the gut-brain axis, gut-brain circuits and gut-restricted and gut-targeted molecules

medical and scientific research in the fields of gastrointestinal diseases, metabolic diseases, microbiome-related conditions, neurological diseases and disorders, and diseases and disorders associated with intestinal permeability; scientific and medical research and development; biological research and development; bacteriological research and development; pharmaceutical scientific research and development; pharmaceutical new product research and development for others; scientific chemical, biochemical, biotechnological, biological and bacteriological research and analysis; providing medical and scientific research information in the fields of pharmaceuticals, biochemistry, biotechnology, and clinical trials; medical and scientific research in the fields of diseases of the gut-brain axis, gut-brain circuits and gut-restricted and gut-targeted molecules

Filing History

APPLICATION FILING RECEIPT MAILED
Sep 9, 2026 MAFR
NEW APPLICATION ENTERED
Sep 9, 2026 NWAP